Hea Young Cho

전공Pharmaceutics

연락처 031-881-7167 hycho@cha.ac.kr

학력

B.S. in Pharmacy, College of Pharmacy, Chonnam National University
M.S. in Biopharmaceutics, College of Pharmacy, Chonnam National University
Ph.D. in Biopharmaceutics, College of Pharmacy, Chonnam National University
Post-doc. Department of Pharmaceutics, State University of New York at Buffalo, USA

경력

(현) 차의과학대학교 약학대학 부교수
(현) 보건복지부 임상연구급여 평가위원회 위원
(현) 식품의약품안전처 중앙약사심의위원회(전문가)위원
(현) 건강보험심사평가원 약제급여평가위원회 위원
(현) 한국연구재단 연구윤리위원회 위원
(현) (사)대학연구윤리협의회 집행이사
(현) (사)한국약제학회 부회장/이사
(현) 약학교육협의회 보건의약관계법규분과회 부회장
식품의약품안전청 보건연구관

[수상경력]

2017 식품의약품안전처 연구개발사업 우수상, 2018.03.28
KAPSA Award of Outstanding Contribution, 한미약학자연합회, 2017.11.14
The Korean-American Pharmaceutical Scientists Association, KAPSA
법제과학상, (사)한국FDC법제학회, 2017.11.09
산학기술상, (사)한국약제학회, 2015.11.19
제25회 과학기술 우수논문상, 한국과학기술단체총연합회, 2015.07.02
업무유공자상(차관급표창), 식품의약품안전청, 2010.01.04
학술장려상, 한국약제학회, 2006.11.30
우수논문발표상, 대한약학회, 2003.10.18
우수학술포스터상, 한국약제학회, 2001.11.15
NAGAI Foundation Awards, Controlled Release Society, 2001.06.27

[연구실 소개]

약물을 체내에 투여하게 되면 흡수 (absorption, A), 분포 (distribution, D), 대사 (metabolism, M) 및 배설 (elimination, E) 등의 과정을 거치게 되는데 이러한 ADME 과정을 속도론적 입장에서 해석하는 학문이 약물속도론 (pharmacokinetics)입니다. 모델을 가정하여 투약 후의 혈중농도, 소실반감기, 대사속도, 배설속도 및 축적량 등을 정량적으로 예측함으로써 ① 생체 내에서의 약물현상의 기구를 해명하고, ② 투여량, 투여간격 및 투여 제형을 적절히 결정하며, ③ 나아가서는 보다 유효하고 안전성이 높은 의약품의 개발에 기여하고자 하는 것을 목적으로 합니다.
우리 연구실은 동물실험에서 약물의 체내동태를 속도론적으로 해석하여 분포용적, 속도정수 등의 파라미터를 산출한 후 animal scale-up의 방법으로 동물 데이터로부터 사람의 약물동태를 예측하고, 또한 약물 농도(PK)와 약물 효과(PD)를 연결할 수 있는 모델 구축 연구를 수행하고 있어, 실제 환자에게 약물의 효과가 충분히 발휘되고 안전성이 확보되도록 하는 약물 투여 용법 적정화에 기여할 수 있을 것으로 기대하고 있습니다.

논문

Population pharmacokinetic modeling and simulation of choline in healthy Korean subjects after oral administration of choline alfoscerate, Pharm. Invest., DOI: 10.1007/s40005-022-00562-2, in press (2022)
In vitro and in vivo evaluations of a 3-month sustained-release microsphere depot formulation of leuprolide acetate, Pharm. Invest., 52, 129-138 (2022)
Long-acting injectable donepezil microspheres: Formulation development and evaluation, Control. Release, 340, 72-86 (2021)
Toxicokinetics of di-isodecyl phthalate and its major metabolites in rats through the application of a developed and validated UHPLC-ESI-MS/MS method, Toxicol., 95(11), 3515-3537 (2021)
Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704, Pharmaceutics, 13(9), 1406, DOI: 10.3390/pharmaceutics13091406 (2021)
Toxicokinetic studies of di-isobutyl phthalate focusing on the exploration of gender differences in rats, Chemosphere, 286, DOI: 10.1016/j.chemosphere.2021.131706 (2021)
Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects, Pharmaceutics, 13(5), 754, DOI: 10.3390/pharmaceutics13050754 (2021)
Palmul-Tang, a Korean Medicine, Promotes Bone Formation via BMP-2 Pathway in Osteoporosis, Front Pharmacol., DOI: 10.3389/fphar.2021.643482 (2021)
Pharmacokinetic-pharmacodynamic modeling approach for dose prediction of the optimal long-acting injectable formulation of finasteride, J. Pharm., DOI: 10.1016/j.ijpharm.2021.120527 (2021)
Human risk assessment of di‑isobutyl phthalate through the application of a developed physiologically based pharmacokinetic model of di‑isobutyl phthalate and its major metabolite mono‑isobutyl phthalate, Toxicol., 95, 2385-2402 (2021)
Evaluation of Lidocaine and Metabolite Pharmacokinetics in Hyaluronic Acid Injection, Pharmaceutics, 12, 374; DOI:10.3390/pharmaceutics13020203 (2021)
Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma, Pharm. Anal., 11 (2021) 351-363
In vivo and in vitro studies of Banhahoobak-tang tablets using UPLC-ESI-MS/MS with polarity switching, Pharm. Biomed. Anal., DOI: 10.1016/j.jpba.2021.113931 (2021)
Simultaneous determination of fourteen components of Gumiganghwal-tang tablet in human plasma by UPLC-ESI-MS/MS and its application to pharmacokinetic study, Pharm. Anal., 11 (2021) 444-457
Simultaneous determination of asarinin, β-eudesmol, and wogonin in rats using UPLC-MS/MS and its application to pharmacokinetic studies following administration of standards and Gumiganghwal-tang, Chromatogr., DOI: 10.1002/bmc.5021 (2020)
Simultaneous determination of three iridoid glycosides of Rehmannia glutinosa in rat biological samples using a validated hydrophilic interaction?UHPLC?MS/MS method in pharmacokinetic and in vitro studies, Sep. Sci., 43(22), 4148-4161 (2020)
Toxicokinetics of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rats: UPLC-ESI-MS/MS method development for the simultaneous determination of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rat plasma, urine, feces, and 11 various tissues collected from a toxicokinetic study, Food Chem. Toxicol., DOI: 1016/j.fct.2020.111747 (2020)
Pharmacokinetics of bioactive components after oral administration of Bojungikgi-tang in Korean subjects, Pharm. Invest., 50(6), 593-602 (2020)
Population Pharmacokinetic analysis of tiropramide in healthy Korean subjects, Pharmaceutics, 12, 374-385 (2020)
Simultaneous measurement of epinastine and its metabolite, 9,13b-dehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies, Chromatogr., DOI: 10.1002/bmc.4848 (2020)
Risk assessment for humans using physiologically based pharmacokinetic model of diethyl phthalate and its major metabolite, monoethyl phthalate, Toxicol., 94(7), 2377-2400 (2020)
Gender differences in pharmacokinetics of perfluoropentanoic acid using non-linear mixed effect modeling in rats, Toxicol., 94(5), 1601-1612 (2020)
Translational toxicology of sex specific PFNA clearance in rat and human, Toxicol., 94(2), 649-650 (2020)
A Novel Eye Drop Candidate for Age-Related Macular Degeneration Treatment: Studies on its Pharmacokinetics and Distribution in Rats and Rabbits, Molecules, 25, 663 (2020)
Pharmacokinetic comparison of epinastine using developed human plasma assays, Molecules, 25, 209 (2020)
Development of level a in vitro–vivo correlation for electrosprayed microspheres containing leuprolide: physicochemical, pharmacokinetic, and pharmacodynamic evaluation, Pharmaceutics, 12(1), 36 (2020)
A sensitive UPLC-ESI-MS/MS method for the quantification of cinnamic acid in vivo and in vitro: application to pharmacokinetic and protein binding study in human plasma, Pharm. Invest., 50(2), 159-172 (2020)
Population pharmacokinetics of cis-, trans-, and total cefprozil in healthy male Koreans, Pharmaceutics, 11, 531 (2019)
Gender differences in pharmacokinetics and tissue distribution of 4‑n‑nonylphenol in rats, Toxicol., 93(11), 3121-3139 (2019)
Response to Hethey et al., 2019 Letter to the Editor in Archives of Toxicology, Toxicol., 93(10), 3033-3035 (2019)
Simultaneous determination of fourteen main active components in Gumiganghwal-tang tablet by using a newly developed UPLC-ESI-MS/MS method, Chromatogr. B, 1126-1127, DOI 10.116/ /j.jchromb.2019.121743, 1126-1127, 121743 (2019)
Simultaneous determination diethyl phthalate and its major metabolite, monoethyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study by ultrahigh performance liquid chromatography-tandem mass spectrometry, Pharm. Biomed. Anal., 173 (2019), 108-119 (2019)
Interpretation of non-clinical data for prediction of human pharmacokinetic parameters: In vitro–in vivo extrapolation and allometric scaling, Pharmaceutics, 11, 168 (2019)
Exploring sex-differences in human health risk assessment for PFNA and PFDA using a PBPK model, Toxicol., 93(2), 311-330 (2019)
Comparison of UPLC-MS/MS and HPLC-UV method for the determination of zaltoprofen in human plasma, Pharm. Invest., 49(6), 613-624 (2019)
Pharmacokinetics profile of Kaurenoic acid after oral administration of Araliae Continentalis Radix extract powder to humans, Pharmaceutics, 10(4), 253 (2018)
Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery, Pharm. Res., 41, 797-814 (2018)
Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to Pharmacokinetic Study, Chromatogr. B, 1095, 214-225 (2018)
Simultaneous Determination of Decursin, Decursinol Angelate, Nodakenin, and Decursinol of Angelica gigas Nakai in Human Plasma by UHPLC-MS/MS: Application to Pharmacokinetic Study, Molecules, 23(5), 1019 (2018)
Pharmacokinetic/Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats, Molecules, 23(4), 909 (2018)
Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach, J. Pharm. Sci., 118, 154-164 (2018)
Research on the advancement of standards and specifications of biologics in Korea, Biologicals, 53, 76-77 (2018)
Bioequivalence of a fixed-dose repaglinide/metformin combination tablet and equivalent doses of repaglinide and metformin tablets, J. Clin. Pharmacol. Ther., 56(6), 292-300 (2018)
Sex-specific risk assessment of PFHxS using a physiologically based pharmacokinetic model, Arch. Toxicol., 92, 1113-1131 (2018)

저서/역서/편서

임상실무 약학, 도서출판 신일북스 (2020) ISBN 978-89-5702-483-6
제2호 한국임상시험백서, 도서출판 국가임상시험지원재단/보건복지부 (2019) ISBN 978-89-9691-091-6
약제학리뷰, 도서출판 신일서적 (2019) ISBN 979-11-8884-754-9
생물약제학과 약동학(수정2판), 도서출판 신일서적 (2019) ISBN 979-11-8884-737-2
임상시험 길잡이, 도서출판 한국보건산업진흥원/보건복지부 (2018)
한국임상시험백서, 도서출판 한국임상시험산업본부 (2016) ISBN 978-89-9691-091-6
약국실무, 도서출판 신일북스 (2016) ISBN 978-89-5702-452-2
약제학 리뷰(수정판), 도서출판 신일북스 (2016) ISBN 978-89-5702-395-2
약제학총서2 수정판 생물약제학과 약동학, 도서출판 신일북스 (2015) ISBN 978-89-5702-431-7
조제학, 도서출판 신일북스 (2015) ISBN 978-89-5702-419-5
약제학리뷰, 도서출판 신일북스 (2014) ISBN 978-89-5702-395-2
생물약제학과 약동학, 도서출판 신일북스 (2013) ISBN 978-89-5702-349-1
약물상호작용의 기전적 이해, 도서출판 신일상사, (2005) ISBN 89-5702-083-7

[특허]

생리학적 약물동태학 핵심 모델. 출원 2020.11.23
전기분무기술을 이용한 루프롤라이드 함유 서방성미립구의 제조방법. 출원(제17-108842호) 2017.08.28
L-THP를 유효성분으로 포함하는 약물남용 치료제. 등록 (제10-1054093호) 2011.07.28